In patients with breast or ovarian carcinomas, higher CCR9 expression in cancer tissues correlate with disease severity, and CCR9 expressing cancer cells migrate and invade under a chemotactic gradient of CCL25 via up-regulation of matrix metalloproteinases (MMPs) [10-12]. This evidence concerns the gene CCR9 and ovarian carcinoma.